Eton Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Eton Pharmaceuticals

18/03/2025 13:32

Eton Pharmaceuticals Inc ETON.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -9 cents.  The mean expectation of three analysts for the quarter was for breakeven results per share. Wall Street expected results to range from -4 cents to 2 cents per share.

Revenue rose 59.3% to $11.65 million from a year ago; analysts expected $10.53 million.

Eton Pharmaceuticals Inc's reported EPS for the quarter was a loss of 2 cents​.

The company reported a quarterly loss of $598 thousand.

Eton Pharmaceuticals Inc shares had risen by 14.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 66.7% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $23.00

This summary was machine generated from LSEG data March 18 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
0.00
-0.02
Missed
Sep. 30 2024
-0.01
0.03
Beat
Jun. 30 2024
-0.07
-0.12
Missed
Mar. 31 2024
-0.04
-0.03
Beat